Radiation administered as a large single dose or in a fractionated schedule: Role of the tumour vasculature as a target for influencing response

References

• Fletcher GH. Regaud Lecture: Perspectives on the history of radiotherapy. Radiother Oncol 1988; 12: 253–71
   Google Scholar
• Baumann M, Saunders MI, Joiner MC. Modified fractionation. In: Steel GG, editor. Basic Clinical Radiobiology. 3rd ed. London: Arnold; p 147–57.
   Google Scholar
• Solberg TD, Selch MT, Smathers JB, DeSalles AAF. Fractionated stereotactic radiotherapy: Rationale and methods. Med Dos 1998; 23: 209–19
   PubMedGoogle Scholar
• Trott KR. Tumour stem cells: The biological concept and its application in cancer treatment. Radiother Oncol 1994; 30: 1–5
   PubMed Web of Science ®Google Scholar
• Hendry JH, West CML, Moore JV, Potten CS. Tumour stem cells: The relevance of predictive assays for tumour control after radiotherapy. Radiother Oncol 1994; 30: 11–6
   PubMed Web of Science ®Google Scholar
• Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155–9
   PubMed Web of Science ®Google Scholar
• Fuss M, Wenz F, Essig M, Muenter M, Debus J, Herman TS, et al. Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. Int J Radiat Oncol Biol Phys 2001; 51: 478–82
   PubMed Web of Science ®Google Scholar
• Tsien C, Souhami L, Sadikot A, Olivier A, Del Carpio-O'Donovan R, Corns R, et al. Stereotactic radiosurgery in the management of angiographically occult vascular malformations. Int J Radiat Oncol Biol Phys 2001; 50: 133–8
   PubMedGoogle Scholar
• Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980; 6: 1507–17
   PubMed Web of Science ®Google Scholar
• Pintaske J, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen CD, et al. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006; 41: 213–21
   PubMed Web of Science ®Google Scholar
• Steel GG. Cell survival as a determinant of tumour response. In: Steel GG, editor. Basic Clinical Radiobiology. 3rd ed. London: Arnold; p 52–63.
   Google Scholar
• Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue?. Cancer Res 1986; 46: 467–73
   PubMed Web of Science ®Google Scholar
• Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: A dynamic theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999; 59: 4770–5
   PubMed Web of Science ®Google Scholar
• Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FALM, Horsman MR, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005; 11: 416–20
   PubMed Web of Science ®Google Scholar
• Stenstrom KW, Vermund H, Mosser DG, Marvin JF. Effects of roentgen irradiation on the tumor bed. I. The inhibiting action of local pretransplantation roentgen irradiation (1500 ra) on the growth of mouse mammary carcinoma. Radiat Res 1955; 2: 180–91
   PubMed Web of Science ®Google Scholar
• Hewitt HB, Blake ER. The growth of transplanted murine tumours in pre-irradiated sites. Br J Cancer 1968; 22: 808–24
   PubMed Web of Science ®Google Scholar
• Suit HD, Willers H. Comment on “tumor response to radiotherapy regulated by endothelial cell apoptosis” (I). Science 2003; 302: 1894
   PubMedGoogle Scholar
• Brown M. Comment on “tumor response to radiotherapy regulated by endothelial cell apoptosis” (II). Science 2003; 302: 1894
   PubMedGoogle Scholar
• Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer 2005; 92: 1599–610
   PubMed Web of Science ®Google Scholar
• Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61: 6413–22
   PubMed Web of Science ®Google Scholar
• Baguley BC, Ching L-M. DMXAA: An antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys 2002; 54: 1503–11
   PubMed Web of Science ®Google Scholar
• de Lussanet QG, Backes WH, Griffioen AW, van Engelshoven JMA, Beets-Tan RGH. Gadopentate dimeglumine versus ultrasmall super-paramagnetic iron oxide for dynamic contrast-enhanced MR imaging of tumor angiogenesis in human colon carcinoma in mice. Radiol 2003; 229: 429–38
   PubMedGoogle Scholar
• Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P, et al. Tumor microvascular changes in antiangiogenic treatment:assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 2004; 20: 138–44
   PubMed Web of Science ®Google Scholar
• Bentzen L, Vestergaard-Poulsen P, Nielsen T, Overgaard J, Bjørnerud A, Briley-Sæbø K, et al. Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor. Int J Radiat Oncol Biol Phys. 2005; 61: 1208–15
   PubMed Web of Science ®Google Scholar
• Horsman MR, Siemann DW. Pathophysiological effects of vascular targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; ( in press).
   PubMedGoogle Scholar